Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 1/2007

01-01-2007 | Review Article

Neutrophilic Folliculitis and the Spectrum of Pyoderma Gangrenosum in Inflammatory Bowel Disease

Authors: A. P. Ruhl, J. E. Ganz, S. J. Bickston

Published in: Digestive Diseases and Sciences | Issue 1/2007

Login to get access

Excerpt

Pyoderma gangrenosum (PG) is a rare dermatologic manifestation of systemic disease. It is most often associated with inflammatory bowel disease (IBD) and can be seen in several other illnesses including immunosuppression, certain forms of arthritis, monoclonal gammopathy, and malignancy [1]. This review of PG as an extraintestinal manifestation of IBD highlights the importance of early and accurate diagnosis so that proper treatment may be initiated. …
Literature
1.
Powell FC, Ahmadi S (2005) Pyoderma gangrenosum: uncommon presentations. Clin Dermatol 23:612–620PubMedCrossRef
2.
Weenig RH, Davis MDP, Dahl PR, Daniel Su WP (2002) Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Medicine 347:1412–1418CrossRef
3.
Kuner N, Hartschuh W (2000) Darstellung des Pyoderma gangraenosum in einem dermatologishcen Atlas des fruehern 19, Jahrhunderts. Hautarzt 51:519–523PubMedCrossRef
4.
Devergie MN (1826) Clinique de la Maladie Syphilitique, Atlas colorie. FM Maurice, Libraire editeur, Paris
5.
Brunstig LA, Goeckerman WH, O’Leary PA (1930) Pyoderma (ecthyma) gangrenosum. Clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syphilol 22:655–680
6.
Vignon-Pennamen MD, Wallach D (1991) Cutaneous manifestations of neutrophilic disease: a study of seven cases. Dermatogica 183:255–264CrossRef
7.
Van den Driesch P (1997) Pyoderma gangrenosum:a report of 44 cases with f follow-up. Br J Dermatol 137:1000–1005CrossRef
8.
Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB, White WL, Callen JP (2000) Pyoderma gangrenosum: a comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine 79:37–46
9.
Perry HO, Brunstig LA (1957) Pyoderma gangrenosum. A clinical study of nineteen cases. Am Med Assoc Arch Dermatol 75:380–386
10.
Prystowsky JH, Khan SN, Lazarus GS (1989) Present status of pyoderma gangrenosum: review of 21 cases. Arch Dermatol 125:57–64PubMedCrossRef
11.
Mir-Madjlessi SH, Taylor JS, Farmer RG (1985) Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol 80:615–620PubMed
12.
Levitt MD, Ritchie JK, Lennard-Jones JE, Phillips RKS (1991) Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg 78:676–678PubMedCrossRef
13.
Sapienza MS, Cohen S, Dimarino AJ (2004) Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci 49:1454–1457PubMedCrossRef
14.
Mimouni D, Anhalt GJ, Kouba DJ, Nousari HC (2003) Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 148:813–816PubMedCrossRef
15.
Su CG, Judge TA, Lichtenstein GR (2002) Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 31:307–327PubMedCrossRef
16.
Das KM (1999) Relationship of extraintestinal involvements in inflammatory bowel disease; new insights into autoimmune pathogenesis. Dig Dis Sci 44:1–13PubMedCrossRef
17.
Manguso F, Sanges M, Staiano T, Gargiulo S, Nastro P, GArgano D, Somma P, Mansueto G, Peluso R, Scarpa R, D’Armiento FP, Astarita C, Ayala F, Renda A, Mazzacca G, D’Arienzo A (2004) cigarrette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis. Am J Gastroenterol 99:327–334PubMedCrossRef
18.
Powell FC, Su D, Perry HO (1996) Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 34(3):395–409PubMedCrossRef
19.
20.
Papageogiou KI, Mathew RG, Kaniorou-Larai MG, Yiakoumetis A (2005) Pyoderma gangrenosum in ulcerative colitis:considerations for an early diagnosis. Br Med J 331:1323–1324CrossRef
21.
Byrne JPH, Hewitt M, Summerly R (1976) Pyoderma gangrenosum associated with chronic active hepatitis:report of two cases. Arch Dermatol 112:1297– 1230PubMedCrossRef
22.
Powell FC, Schroeter AL, Daniel Su WP (1985) Pyoderma gangrenosum: a review of 86 patients. Q J Med 55:173–186PubMed
23.
Thornton JR, Teague RJ, Low-Bier TS, et al. (1980) Pyoderma gangrenousm in ulcerative colitis. Gut 21:247–248PubMedCrossRef
24.
Das KM, Dubin R, Nagai T (1978) Isolation and characterization of colonic tissue bound antibodies from patients with idiopathic ulcerative colitis. Proc Natl Acad Sci USA 75:4528–4532PubMedCrossRef
25.
Geng X, Baincone L, Dai HH, Lin J, Yoshizaki N, Dasgupta A, Pallone F, Das KM (1998) Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology 114:912–922PubMedCrossRef
26.
O’Loughlin S, Perry HO (1978) A diffuse pustular eruption associated with ulcerative colitis. Arch Dermatol 114:1061–1064PubMedCrossRef
27.
28.
Fenske NA, Gern JE, Pierce D, Vasey FB (1983) Vesiculopapular eruption of ulcerative colitis. Arch Dermatol 119:664–669PubMedCrossRef
29.
Callen JP, Woo TY (1985) Vesiculopapular eruption of ulcerative colitis. Arch Dermatol 121:339–344CrossRef
30.
31.
Finkel SI, Janowitz HD (1981) Trauma and pyoderma gangrenosum of inflammatory bowel disease. Gut 22:410–412PubMedCrossRef
32.
Moschella SL (2005) Neutrophilic dermatoses. Available at: uptodate.com
33.
Barnes L, Lucky AW, Bucuvalas JC, Suchy FJ (1986) Pustular pyoderma gangrenosum associated with ulcerative colitis in childhood. J Am Acad Dermatol 15:608–614PubMedCrossRef
34.
Dicken CH (1986) Bowel-associated dermatosis-arthritis syndrome: bowel bypass syndrome without bowel bypass. J Am Acad Dermatol 14:792–796PubMed
35.
Delaney TA, Clay CD, Randell PL (1989) The bowel-associated dermatosis- arthritis syndrome. Australas J Dermatol 30:23–27PubMedCrossRef
36.
Van Hale H, Rogers RS, Zone JJ (1985) Pyostomatitis vegetans: a reactive mucosal marker for inflammatory disease of the gut. Arch Dermatol 121:67–77CrossRef
37.
Basler RS (1980) Ulcerative colitis and the skin. Med Clin North Am 64:941–954PubMed
38.
Hughes AP, Jackson JM, Callen JP (2000) Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 284:1546–1548PubMedCrossRef
39.
Blitz NM, Rudikoff D (2001) Pyoderma gangrenosum. Mt Sinai J Med 68:287– 297PubMed
40.
Brooklyn TN, Dunnill GS, Shetty A, Bowden JJ, Williams JDL, Griffiths CEM, Forbes AEM, Greenwood R, Probert CS (2005) Infliximab for the treatment of pyoderma gangrenosum:a randomized, double-blind placebo-controlled trial. Gut doi:10.1136/gut.2005.074815
41.
Reichrath J, Bens G, Bonowitz A, Tilgen W (2005) Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 53:273–283PubMedCrossRef
42.
43.
Reich K, Vente C, Neumann C (1998) Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol 139:755–757PubMedCrossRef
44.
Chiba T, Isomura I, Suzuki A, Morita A (2005) Topical tacrolimus therapy for pyoderma gangrenosum. J Dermatol 32:199–203PubMed
45.
Powell RJ, Holbrook MR, Stevens A (1997) Pyoderma gangrenosum and its treatment. Lancet 350:1720–1721PubMedCrossRef
46.
Matis WL, Ellis CN, Griffiths CEM, Lazarus GS (1992) Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 128:1060–1064PubMedCrossRef
47.
Hong JJ, Merel NH, Hanauer SB (2001) Treatment of pyoderma gangrenosum complicating Crohn's disease with infliximab. Gastroenterology 120:A621CrossRef
48.
Brooklyn TN et al. (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55:505--509PubMedCrossRef
49.
Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417–429
50.
Trost LB, McDonnell JK (2005) Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 81:580–585PubMedCrossRef
51.
52.
Cox NH, Peebles-Brown DA, Mackie RM (1986) Pyoderma gangrenosum occurring 10 years after proctocolectomy for ulcerative colitis. Br J Hosp Med 36:363PubMed
53.
Su DWP, Davis MDP, Weenig RH, Powell FC, Perry HO (2004) Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Into J Dermatol 43:790–800CrossRef
Metadata
Title
Neutrophilic Folliculitis and the Spectrum of Pyoderma Gangrenosum in Inflammatory Bowel Disease
Authors
A. P. Ruhl
J. E. Ganz
S. J. Bickston
Publication date
01-01-2007
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9361-4

Other articles of this Issue 1/2007

Digestive Diseases and Sciences 1/2007 Go to the issue

Original Paper

Nine-Year Single-Center Experience with Nonparastic Liver Cysts: Diagnosis and Management

Original Paper

Fructo-oligosaccharide Reduces Inflammation in a Dextran Sodium Sulphate Mouse Model of Colitis

Original Paper

Expression of IGFBP2 in Gastric Carcinoma and Relationship With Clinicopathologic Parameters and Cell Proliferation

Original Paper

The Effect of Oral α-Galactosidase on Intestinal Gas Production and Gas-Related Symptoms

Original Paper

Canonical Correlation Analysis of Factors Involved in the Occurrence of Peptic Ulcers

Original Paper

Does Adding Misoprostol to Standard Intravenous Proton Pump Inhibitor Protocol Improve the Outcome of Aspirin/NSAID-Induced Upper Gastrointestinal Bleeding?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits